Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis

Seminars in Neurology

Volumn 18, Issue 3, 1998, Pages 327-336

  Matthews, P M ^a   De Stefano, N ^b   Narayanan, S ^d   Francis, G S ^d   Wolinsky, J S ^c   Antel, J P ^d   Arnold, D L ^c,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Axons; Disability; Magnetic resonance spectroscopy; MRI; Multiple sclerosis; N acetyl aspartate

Indexed keywords

N ACETYLASPARTIC ACID;

CELL INTERACTION; DISEASE COURSE; FUNCTIONAL ASSESSMENT; GLIA CELL; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSICAL DISABILITY; PRIORITY JOURNAL; REVIEW;

EID: 0031769822     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040884     Document Type: Review

References (51)

1. Raine CS. The neuropathology of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: Clinical and pathogenetic basis. London: Chapman & Hall, 1997: 151-171
2. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991;114: 2437-2450
3. Utzschneider DA, Thio C, Sontheimer H, Ritchie JM, Waxman SG, Kocsis JD. Action potential conduction and sodium channel content in the optic nerve of the myelin-deficient rat. Proc R Soc Lond Ser B Biol Sci 1993;254:245-250
4. Rivera-Quinones CMD, Schmelzer JD, Hunter SF, Low PA, Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nature Med 1998;4:187-193
5. Chiu SY, Ritchie JM. Evidence for the presence of potassium channels in the paranodal region of acutely demyelinated mammalian single nerve fibres. J Physiol 1981;313:415-437
6. Waxman SG, Ritchie JM. Organization of ion channels in the myelinated nerve fiber. Science 1985;228:1502-1507
7. England JD, Gamboni F, Levinson SR, Finger TE. Changed distribution of sodium channels along demyelinated axons. Proc Natl Acad Sci USA 1990;87:6777-6780
8. Moll C, Mourre C, Lazdunski M, Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 1991;556:311-316
9. Brosnan CF, Litwak MS, Schroeder CE, Selmaj K, Raine CS, Arezzo JC. Preliminary studies of cytokine-mduced functional effects on the visual pathways in the rabbit. J Neuroimmunol 1989;25:227-239
10. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119(Pt 1):225-237
11. Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers [see comments]. CM-Comment in Ann Neurol 1995;37:421-423; SO-Ann Neurol 1995;37:436-442; MH-Action Potentials/im [Immunology]
12. Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers [see comments]. CM-Comment in Ann Neurol 1995;37:421-423; SO-Ann Neurol 1995;37:436-442; MH-Action Potentials/im [Immunology]
13. Waxman SG. Sodium channel blockade by antibodies: A new mechanism of neurological disease? [editorial; comment]. CM-Comment in Ann Neurol 1995;37:436-442; SO-Ann Neurol 1995;37:421-423; MH-*Autoantibodies/im [Immunology]; MH-Autoimmunity/ph [Physiology]
14. Waxman SG. Sodium channel blockade by antibodies: A new mechanism of neurological disease? [editorial; comment]. CM-Comment in Ann Neurol 1995;37:436-442; SO-Ann Neurol 1995;37:421-423; MH-*Autoantibodies/im [Immunology]; MH-Autoimmunity/ph [Physiology]
15. Matyszak MK, Townsend MJ, Perry VH. Ultrastructural studies of an immune-mediated inflammatory response in the CNS parenchyma directed against a non-CNS antigen. Neuroscience 1997;78:549-560
16. Campbell IL, Stalder AK, Chiang CS, et al. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997;2:125-129
17. Miller DH, Kesselring J, McDonald WI, eds. Magnetic resonance in multiple sclerosis. Cambridge: Cambridge University Press, 1997
18. Arnold DL, Matthews PM, De Stefano N, Bachelard HS, eds. MRI and proton MRS in the evaluation of multiple sclerosis. New York: Plenum, 1997:267-288
19. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease. Magn Reson Med 1990;14:154-159
20. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published erratum appears in Neurology 1991;41:1828]. Neurology 1991;41:1251-1256
21. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31:235-241
22. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82
23. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. Lancet 1991; 337:58-59
24. Van Hecke P, Marchai G, Johannik K. et al. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med 1991;18:199-206
25. Brunn H, Frahm J, Merboldt KD, et al. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992;32:140-150
26. Grossman RI, Lenkinski RE, Ramer KN, Gonzalezscarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1535-1543
27. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117(Pt 1):49-58
28. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157-165
29. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71
30. Charcot JM. Histologie de le sclerose en plaques. Gazette des Hopitaux 1868:554-558
31. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120(Pt 3):393-399
32. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Lars B. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
33. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion; a quantitative MRI and electron microscopic study. Brain 1991;114:1271-1280
34. Losseff NA, Webb SL, O'Riordan JI, et al Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119(Pt 3):701-708
35. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119(Pt 6):2009-2019
36. 1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47: 1469-1476
37. 1-weighted) spin echo images. Neurology 1995;45:1684-1690
38. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118(Pt 6):1583-1592
39. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis: Results of a longitudinal MR spectroscopy study. Brain (in press)
40. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998;121:103-113
41. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1996;38:901-909
42. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate following acute brain injury. Magn Reson Med 1995;34:721-727
43. Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978;28(suppl 2):68-75
44. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetyl aspartate production: Implications for 1H MRS studies in vivo. NeuroReport 1996;7:1397-1400
45. Matthews PM, Cianfaglia L, McLaurin J, et al. Demonstration of reversible decreases in N-acetyl aspartate (NAA) in a neuronal cell line: NAA decreases as a marker of sublethal neuronal dysfunction [abstract]. Proc Soc Magn Reson Med 1995;1:147
46. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity of pathogenesis [review]. Brain Pathol 1996;6:259-274
47. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40:1764-1769
48. Lee M, Palace J, Narayanan S, et al. Lesion probability mapping for characterisation of the spatial dynamics of disease activity in multiple sclerosis [abstract]. J Neurol 1997;244(suppl 3):S37
49. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
50. Compston DA, Kellar WH, Robertson N, Sawcer S, Wood NW. Genes and susceptibility to multiple sclerosis [review]. Acta Neurol Scand Suppl 1995;161:43-51
51. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis [see comments]. Nature Genet 1996;13: 472-476